This message was sent to ##Email##
|
|
|
|
|
| |
New ADAA Public Statement
Read ADAA’s new public statement FDA Approves Fast-Acting Esketamine for Treatment-Resistant Depression: Clinicians and Researchers are Cautiously Optimistic on the new FDA approval of Spravato. Also - don’t miss #ADAA2019’s Jerilyn Ross Lecture: Ketamine and Mind-Altering Drugs in Treating Anxiety and Depression: Potential Roles and Pitfalls! More information on the lecture and panelists here.
 ADAA Board Applications
Thank you to those members who submitted an application for ADAA’s open board positions. We are very excited with the number and caliber of the applicants. The board nominating committee will be reviewing applications over the new few weeks. We will be announcing the new board members in early April.
ADAA
 Excited for #ADAA2019? We are too! Read ADAA Board President Beth Salcedo’s new blog post If Elephants Could Talk… highlighting this year’s Conference. We look forward to welcoming you to the Windy City in just two weeks.
Still Time to Register.
#ADAA2019 Program Spotlight
The 39th annual ADAA conference offers 150+ sessions on a wide range of topics that will offer a total of 29.5 CE/CME credits! CE registration is free for ADAA members, so be sure to register today.
Our “Not-To-Miss” Invited Sessions!
#ADAA2019 Special Events
Need a New Headshot? We’ve Got You Covered!
Get your free professional headshot at #ADAA2019 with conference photographer Skorburg & Associates Photography! Time and location information will be provided in the printed program and in the mobile app. Lights, Camera, Smile!
Off-Site Event: Therapy Players
Don’t miss Chicago’s Premier All-Psychotherapist Comedy Improv Troupe, featuring ADAA member Dave Carbonell! They have a special invite for ADAA conference attendees for Friday, March 29th at 8pm at the Skokie Theatre. Get tickets and more information at https://www.therapyplayers.com/ and use code “ADAA” for discounted tickets. If you haven’t seen Therapy Players, you haven’t seen Chicago!
Check out the Special Events Webpage for all of the exciting activities and events going on throughout the conference. Check back frequently for updates.
Calling all Food Lovers! Dine-Arounds are Back!
Dine-Arounds for #ADAA2019 will be held on Friday, March 29. Dine-Arounds are a fun way to provide your fellow attendees the opportunity of dining with you and networking with other conference attendees.
If you are an active ADAA member and would like to host a Dine-Around, sign up here.
Interested in signing up to join a Dine-Around? Watch for an email later this week. Sign-up sheets will also be available at the Registration area.
Special thank you to ADAA member Ken Goodman, LCSW for coordinating this year’s Dine-Arounds. Please contact Ken with any questions.
Take Advantage of Discounted Hotel Rates – Book Your Room by THIS Friday, March 15th!
We invite you to take advantage of our newly negotiated and highly competitive rate of $169 per night (single or double room), a $66 savings at the Sheraton Grand Chicago! Be where all the action is!
Book today - the special rate ends Friday, March 15th!
Register for #ADAA2019 and book your hotel room today.
Help Improve Mental Health for the People of Bhutan
 Dr. Karen Cassiday, ADAA Past President, is volunteering in Bhutan at the Jigme Dorji Wangchuck National Referral Hospital and in the Department of Psychiatry at the Khesar Gyalp University of Medical Sciences this June through September 2019.
The national referral hospital and medical university are small and in need of psychiatry and behavioral health textbooks and self-help books. They hope to train nurses to become rural mental health providers. Here is where you can help Bhutan in developing their mental health services. The textbooks and self-help books that you have written would be a valuable and much appreciated gift to the people of Bhutan. You can have a powerful positive impact if you donate the books that you have written to Karen to take to Bhutan.
You do not have to be an author to contribute. If you have some great textbooks or self-help books that you would like to donate, then please join our effort by bring two (2) copies of the book(s) you have written to the ADAA 2019 Conference in Chicago and depositing them in the donation box by the registration booth. One copy apiece will be given to the libraries of the referral hospital and the medical school. Alternately, you can mail your books to:
Karen Cassiday, PhD, ACT
The Anxiety Treatment Center of Greater Chicago
707 Lake Cook Road, Suite 310
Deerfield, IL 60015
Many thanks on behalf of Dr. Cassiday and ADAA.
Thank you to ADAA's Current #ADAA2019 Sponsors
Diamond Sponsor
Rogers Behavioral Health
Gold Sponsors
Sage Therapeutics
VistaGen Therapeutics
Silver Sponsors
American Foundation for Suicide Prevention
Houston OCD Program
Janssen Research and Development LLC
Bronze Sponsors
AMITA Health
Anxiety.org
Barn Life Recovery
Beck Institute for Cognitive Behavioral Therapy
McLean Hospital
Wiley
Thank You to ADAA's Current #ADAA2019 Exhibitors
For details on sponsorship or exhibiting opportunities, please contact Gabby Oved at goved@adaa.org or 240-485-1031.
 |
|
We offer free CE credits for counselors in behavioral health. These webinars provide the opportunity to learn from industry experts, promote effective treatment methods and establish beneficial relationships among treatment professionals. Sign up for a webinar today!
|
|
ADAA
ADAA offers a variety of webinars for mental health professionals. Most ADAA professional webinars offer CE/CME and AWSB credits.
Wednesday, April 10, 2019 — Dean McKay, PhD, ABPP presents:
An Old Approach with a New Twist: Applications of Inhibitory Learning in Exposure Therapy
Eligible for 1 CE/CME hour
Thursday, June 13, 2019 — David Rosmarin, PhD, ABPP presents:
Spirituality & Mental Health: What Clinicians Need to Know
Eligible for 1 CE/CME hour
Based on member survey requests for more interactive educational initiatives, the Public Education Committee is pleased to announce our first online interactive Fall Forum which will address understanding and treating maternal anxiety and depression. The three-hour conversation will include discussions on the following topics:
- Medications for maternal mental health issues
- Medication complexities during pregnancy and nursing
- Challenges associated with mood/anxiety across pregnancy and motherhood
- Maternal MH screening in pregnancy, post-partum, and infant visits
- Psychotherapy interventions for maternal MH issues
Stay tuned for date/time and more details..
Recent ADAA Recordings
Click here for a full listing of all on-demand webinars.
ADAA
ADAA Member News
New! ADAA Membership Benefits Video
 Are you making the most out of your ADAA membership? Watch our new Membership Benefits video hosted by our Membership Director, Lisa Patterson. Lisa will guide you through your many wonderful member benefits. Be sure to also check out the ADAA Membership and Membership Benefits pages as well.
ADAA is proud to showcase the cutting-edge research conducted by our members. If you are interested in featuring your research lab, please download the flyer here or contact Astrid Masfar: amasfar@adaa.org
New ADAA Member Blog Posts
If Elephants Could Talk…Special #ADAA2019 Blog Post
Beth Salcedo, MD - ADAA Board President
“Just Checking” on the Ones We Love
by Jennifer Shannon, LMFT
New ADAA Member Webinars
OCD and Sibling Relationships: How to Cope When Your Brother or Sister Has OCD
by Michelle Witkin, PhD
ADAA
Have you been quoted in a recent news article/story? Please let us know so we can share your news with your ADAA colleagues and with our public community (here, through the website and via our social media platforms).
03/08/2019 The FDA Approve Esketamine Nasal Spray for Severe Depression, MedicalNewsToday.com, Michael Thase, MD
03/07/2019 J&J's Ketamine-Based Drug Drives Sea Change for New Depression Treatments, FoxBusiness.com, Sanjay Mathew, MD
03/06/2019 Advocates Cheer FDA Approval of Anti-Depressant Nasal Spray, WashingtonTimes.com, Sanjay Mathew, MD
03/06/2019 FDA Approves New Johnson & Johnson Drug for Depression, MarketPlace.org, Sanjay Mathew, MD
03/06/2019 When Dealing with Financial Anxiety, Facing Fear is Essential According to ADAA Public Education Committee Co-Chair, RewardExpert.com, Debra Kissen, PhD, MHSA
03/05/2019 Rejections Hurt. Here’s How to Help Your Child During College-Acceptance Season, WashingtonPost.com, Mary Alvord, PhD
03/01/2019 7 Signs Analysis Paralysis Is Causing Issues In Your Relationship, Bustle.com, Ashley Annestedt, LCSW
02/28/2019 Shortage of Antianxiety Drug Leaves Patients in the Lurch, Medscape.com, Beth Salcedo, MD
02/27/2019 How to Stop Comparing Yourself to Others (And What to Do Instead), UpJourney.com, Ashley Annestedt, LCSW
02/25/2019 CBD Is Everywhere, but Scientists Still Don’t Know Much About It, NYTimes.com, Michael Van Ameringen, MD, FRCPC
02/24/2019 My Friend is Struggling But Won't Get Help. What Should I Do?, Tonic.Vice.com, Michelle Lozano, MFT
02/20/2019 Innovative Program Teaches Adults How to Help Teens Who Have Suicidal Thoughts, Healthline.com, Mary Alvord, PhD
02/20/2019 CBT, Supportive Psychotherapy Improve Body Dysmorphia Severity, Healio.com, Douglas Mennin, PhD and Sabine Wilhelm, PhD
Have you published a new book for consumers or professionals? Please let us know so we can highlight your new publication here and on the ADAA website.
ADAA is also interested in highlighting our members' research. Please send us your recent research news for us to post and share.
ADAA
March 2019 Issue — Volume 36, Issue 3
FOCUS ON: TREATMENTS FOR DEPRESSION AND ANXIETY
Highlighted Articles:
Internet‐ and mobile‐based interventions for anxiety disorders: A meta‐analytic review of intervention components
Matthias Domhardt, Helene GeBlein, Roman E. von Rezori, Harald Baumeister
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression
Naji C. Salloum, Maurizio Fava, Marlene P. Freeman, Martina Flynn, Bettina Hoeppner, Rebecca S. Hock, Cristina Cusin, Dan V. Iosifescu, Madhukar H. Trivedi, Gerard Sanacora, ADAA member Sanjay J. Mathew, Charles Debattista, ADAA member Dawn F. Ionescu, George I. Papakostas
Early View Articles:
Explaining the association between anxiety disorders and alcohol use disorder: A twin study
Fartein Ask Torvik, Tom Henrik Rosenström, Kristin Gustavson, Eivind Ystrom, Kenneth S. Kendler, Jørgen G. Bramness, Nikolai Czajkowski, Ted Reichborn‐Kjennerud
Version of Record online: 05 March 2019
Depression and Anxiety, the official journal of the Anxiety and Depression Association of America, is available online at no charge to ADAA members. The journal welcomes original research and synthetic review articles covering neurobiology (genetics and neuroimaging), epidemiology, experimental psychopathology, and treatment (psychotherapeutic and pharmacologic) aspects of mood and anxiety disorders, and related phenomena in humans. Per the ISI Journal Citation Reports Rankings for 2017, the Depression and Anxiety impact factor is 5.043. The journal ranks 19 of 142 in psychiatry journals; 8 of 77 in psychology journals; 5 of 121 for psychology clinical journals, and 15 of 139 for psychiatry social science journals. Google Scholar psychiatry journal ranking (spring 2017) ranked Depression and Anxiety #19 of 20.
Murray B. Stein, MD, MPH - Editor-in-Chief
Meet the Journal Editorial Board
|
|
|
|
|
| |
| | RESEARCH AND PRACTICE NEWS |
Medical News Today
Regulators in the United States have recently approved a new prescription-only nasal spray for use against treatment-resistant depression. The Food and Drug Administration have just granted approval of the drug esketamine to the Johnson & Johnson company Janssen Pharmaceuticals Inc.
The fast-acting nasal spray is for use in conjunction with an oral antidepressant in adults with treatment-resistant depression, note the federal agency.
READ MORE
Marketplace
The Food and Drug Administration has approved the first new kind of drug to treat depression since Prozac hit the scene in the late 1980s. Spravato is a nasal spray from Johnson & Johnson that's a close cousin of ketamine, an anesthetic that's sometimes used recreationally and often known as "Special K." Because ketamine can cause hallucinations and out-of-body experiences, the new drug must be administered in a clinical setting. The drug is designed to start working in hours instead of weeks. It's meant to treat people who have not found relief through other antidepressants.
READ MORE
Psychiatric Times
Anxiety disorders are the most common psychiatric condition in youth. Lifetime prevalence rates for any anxiety disorder in adolescents is 31.9 percent. Anxiety disorders occur early in childhood with a median age of onset of six years. These disorders lead to significant impairment in academic, social, and family functioning. In clinical practice, it is common to see children who are homeschooled because of severe untreated anxiety disorders. Untreated anxiety disorders may also be a precursor for MDD. There have been some recent studies and meta-analyses that address mental health hospitalization, optimal treatment, and long-term outcome for children and adolescents with anxiety disorders.
READ MORE
University of Nevada, Las Vegas News Center
It’s increasingly common to hear about new moms suffering from the baby blues. But what about new dads?
A new UNLV study, published recently in the Journal of Family Issues, offers an in-depth view of new fathers’ experiences with postpartum depression. The study explores issues they encounter and how they can move beyond the barriers they face in receiving diagnoses and treatment of the little-known phenomenon.
READ MORE
HealthDay News via Clinical Advisor
Living around high levels of green space during childhood is associated with a lower risk for a wide spectrum of psychiatric disorders later in life, according to a study published online Feb 25. in the Proceedings of the National Academy of Sciences.
READ MORE
The New York Times
The number of deaths from alcohol, drugs and suicide in 2017 hit the highest level since the collection of federal mortality data started in 1999, according to an analysis by two public health nonprofits, the Trust for America’s Health and the Well Being Trust. To reach their conclusion, the two groups parsed the latest available data from the federal Centers for Disease Control and Prevention.
READ MORE
Yale Daily News
A new study by researchers at the Yale School of Medicine found that depression is associated with a lower density of synapses, which allow communication between brain cells.
As the first researchers to measure the synaptic density of the living brain, the team found that individuals with high levels of depression show significantly lower synaptic density compared to non-depressed individuals or individuals with mild depression. The team’s preliminary data also discovered that depression may be associated with a greater decline in synaptic density with aging, but further studies are required to corroborate this finding.
READ MORE
Bustle
At one point or another, you’ve probably met someone who identifies as “a social drinker” — you may even identify as one yourself. People drink casually for a host of reasons: to help them unwind, because they enjoy the taste, and even as a “social lubricant” to help feel less awkward and make socializing a little easier. While there’s nothing wrong with responsibly sipping some wine or beer at a party, alcohol also has the potential to be misused, particularly when it comes to dealing with social anxiety. A new study found that social anxiety disorder may be linked to substance use disorder, and specifically alcohol use, that weren’t reflected in other types of anxiety disorders.
READ MORE
Pennsylvania State University
Major depressive disorder is increasing among U.S. adolescents, while screening rates for depression remain low and insufficient in addressing the rising mental health crisis, according to data from the National Survey on Drug Use and Health.
A research team lead by Deepa Sekhar, associate professor of pediatrics at Penn State College of Medicine, investigated MDD screening rates among privately insured teens. The research was published recently in the Journal of Pediatrics.
READ MORE
The New York Times
Cannabidiol, or CBD, a nonintoxicating component of the marijuana plant, is touted as a magic bullet that eases pain, anxiety, insomnia and depression. Salves, sprays, tinctures and oils containing CBD are marketed as aphrodisiacs that boost desire; as balms for eczema, pimples and hot flashes; and even as treatments for serious diseases like diabetes and multiple sclerosis.
Unlike THC, or tetrahydrocannabinol, the “psychoactive” component of the cannabis plant, CBD won’t get you “high.” But scientists know little about what it can do: most of the information about CBD’s effects in humans is anecdotal or extrapolated from animal studies, and few rigorous trials have been conducted.
READ MORE
University of Liverpool via Medical Xpress
New research, conducted by the University of Liverpool and University College London, has found that young people today are more likely to be depressed and to self-harm than they were 10 years ago, but antisocial behavior and substance use – often thought to go hand-in-hand with mental ill-health – are in decline.
Instead, the study, published in the International Journal of Epidemiology, found poor sleep, obesity and poor body image are becoming more common, suggesting the risk factors associated with mental ill-health might be changing.
READ MORE
Healio
Maternal infection during pregnancy significantly increased the risk for depression and autism spectrum disorder in offspring, according to a Swedish population-based cohort study published in JAMA Psychiatry.
“Whether maternal infection and inflammation can alter fetal neurodevelopment to a degree that imparts risk for a broad spectrum of psychopathologic conditions across the child’s lifetime is unknown,” Benjamin J. S. al-Haddad, MD, PhD, from the department of pediatrics, Seattle Children’s Hospital and University of Washington, and colleagues wrote.
READ MORE
Science Magazine
Insomnia, often blamed on stress or bad sleep habits, may instead be closely linked to depression, heart disease, and other physiological disorders, a pair of deep dives into the human genome now reveals.
“Both studies are very well done,” says psychologist Philip Gehrman of the University of Pennsylvania’s Perelman School of Medicine, who researches sleep behavior. Still, he stresses that much more work remains before the genetic connections to insomnia can be translated to new therapies for patients.
READ MORE
The Fix
Individuals in and out of the medical community have long been fascinated with psychedelic drugs and their short- and long-term mind-altering effects.
Some people with depression believe the drugs have the ability to treat mental health disorders, and new research indicates they may be right. A study published in the journal ACS Chemical Neuroscience found that rats who received tiny doses of the psychedelic N,N-dimethyltryptamine experienced an antidepressant effect, but no negative effects on their memories.
READ MORE
UPI
For years, doctors have debated the safety of the acne drug most commonly known as Accutane, but new research suggests the medication does not boost depression risk among its users.
"The existing literature to date is quite mixed with regards to the issue of whether there is or is not an association between isotretinoin [Accutane] use and increased risk of depression," explained study author Dr. Bethanee Schlosser. "Our retrospective, population-based study shows no increased risk of depression in patients taking isotretinoin, compared to patients with acne but not taking isotretinoin," she said.
READ MORE
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
